[1] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[2] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[3] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[4] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[5] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[6] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[7] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[8] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[9] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[10] |
ZHENG Jinfeng, WANG Jinghong.
Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
|
[11] |
SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying.
Pharmaceutical care of a patient with indapamide-induced agranulocytosis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
|
[12] |
WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui.
Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
|
[13] |
WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui.
Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.
|
[14] |
SU Xinxin, ZHAO Xiaoxiao, XIE Yanming.
Real-world analysis of combined administration of elemene emulsion injection in patients with liver cancer
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 929-934.
|
[15] |
HUANG Yanli, XIE Yanming, WANG Lianxin, SUN Linxi, LIU Huan, ZHUANG Yunni.
Clinical applications of Ciwujia injection in elderly patients in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 935-939.
|